Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis

Journal of Psychiatric Research

Volumn 43, Issue 8, 2009, Pages 792-797

  Pjrek, Edda ^a   Konstantinidis, Anastasios ^a   Assem Hilger, Eva ^a   Praschak Rieder, Nicole ^a   Willeit, Matthäus ^a   Kasper, Siegfried ^a   Winkler, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; Depression; Escitalopram; Noradrenaline; Pharmacotherapy; Reboxetine; Seasonal affective disorder; Serotonin

Indexed keywords

ESCITALOPRAM; REBOXETINE;

ACCOMMODATION DISORDER; AGITATION; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRY EYE; FATIGUE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERSALIVATION; INSOMNIA; LIBIDO DISORDER; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; REMISSION; SEASONAL AFFECTIVE DISORDER; SIDE EFFECT; SOCIAL ADAPTATION; SWEATING; TREMOR; URINE RETENTION; VERTIGO; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; CITALOPRAM; CLINICAL TRIALS AS TOPIC; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES; SEASONAL AFFECTIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 64249124999     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.11.004     Document Type: Article

References (36)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM-IV). fourth ed. (1994), American Psychiatric Press, Washington, DC
2. Andreoli V., Caillard V., Deo R.S., Rybakowski J.K., and Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. Journal of Clinical Psychopharmacology 22 (2002) 393-399
3. Bech P., Allerup P., Gram L.F., Reisby N., Rosenberg R., Jacobsen O., et al. The Hamilton depression scale: evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica 63 (1981) 290-299
4. Berlanga C., and Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Journal of Affective Disorders 95 (2006) 119-123
5. Bosc M., Dubini A., and Polin V. Development and validation of a social functioning scale, the social adaptation self-evaluation scale. European Neuropsychopharmacology 7 suppl. 1 (1997) 57-70 [discussion 1-3]
6. Chen F., Larsen M.B., Sanchez C., and Wiborg O. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neuropsychopharmacology 15 (2005) 193-198
7. Coiro V., Volpi R., Marchesi C., De Ferri A., Davoli C., Caffarra P., et al. Abnormal serotonergic control of prolactin and cortisol secretion in patients with seasonal affective disorder. Psychoneuroendocrinology 18 (1993) 551-556
8. Dilsaver S.C., Qamar A.B., and Del Medico V.J. The efficacy of bupropion in winter depression: results of an open trial. Journal of Clinical Psychiatry 53 (1992) 252-255
9. Eker S.S., Akkaya C., Akgöz S., Sarandöl A., and Kirli S. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Dergisi 16 (2005) 153-163
10. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
11. Hilger E., Willeit M., Praschak-Rieder N., Stastny J., Neumeister A., and Kasper S. Reboxetine in seasonal affective disorder: an open trial. European Neuropsychopharmacology 11 (2001) 1-5
12. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6 (1979) 65-70
13. Kasper S., el Giamal N., and Hilger E. Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opinion on Pharmacotherapy 1 (2000) 771-782
14. Klein N., Sacher J., Geiss-Granadia T., Mossaheb N., Attarbaschi T., Lanzenberger R., et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berlin) 191 (2007) 333-339
15. Langworth S., Bodlund O., and Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Journal of Clinical Psychopharmacology 26 (2006) 121-127
16. Linden M., Baier D., Beitinger H., Kohnen R., Osterheider M., Philipp M., et al. Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" task-force of the association for neuropsychopharmacology and pharmacopsychiatry (AGNP). Pharmacopsychiatry 30 Suppl. (1997) 65-70
17. Lingjærde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 76 Suppl. 334 (1987) 1-100
18. Massana J., Möller H.J., Burrows G.D., and Montenegro R.M. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. International Clinical Psychopharmacology 14 (1999) 73-80
19. Nelson J.C., Portera L., and Leon A.C. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. Journal of Clinical Psychiatry 66 (2005) 1409-1414
20. Neumeister A., Turner E.H., Matthews J.R., Postolache T.T., Barnett R.L., Rauh M., et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Archives of General Psychiatry 55 (1998) 524-530
21. Neumeister A., Willeit M., Praschak-Rieder N., Asenbaum S., Stastny J., Hilger E., et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychological Medicine 31 (2001) 1467-1473
22. Pjrek E., Willeit M., Praschak-Rieder N., Konstantinidis A., Semlitsch H.V., Kasper S., et al. Treatment of seasonal affective disorder with duloxetine: an open-label study. Pharmacopsychiatry 41 (2008) 100-105
23. Pjrek E., Winkler D., Stastny J., Konstantinidis A., Heiden A., and Kasper S. Bright light therapy in seasonal affective disorder - does it suffice?. European Neuropsychopharmacology 14 (2004) 347-351
24. Pjrek E., Winkler D., Stastny J., Praschak-Rieder N., Willeit M., and Kasper S. Escitalopram in seasonal affective disorder: results of an open trial. Pharmacopsychiatry 40 (2007) 20-24
25. Rampello L., Chiechio S., Nicoletti G., Alvano A., Vecchio I., Raffaele R., et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berlin) 173 (2004) 73-78
26. Rosenthal N.E., Sack D.A., Gillin J.C., Lewy A.J., Goodwin F.K., Davenport Y., et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry 41 (1984) 72-80
27. Schwartz P.J., Murphy D.L., Wehr T.A., Garcia-Borreguero D., Oren D.A., Moul D.E., et al. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. Archives of General Psychiatry 54 (1997) 375-385
28. SPSS Inc. SPSS for Windows. Release 15.0. Chicago, IL USA; 1989-2006.
29. Stastny J., Konstantinidis A., Schwarz M.J., Rosenthal N.E., Vitouch O., Kasper S., et al. Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy. Biological Psychiatry 53 (2003) 332-337
30. Taner E., Demir E.Y., and Cosar B. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial. Advances in Therapy 23 (2006) 974-987
31. Willeit M., Praschak-Rieder N., Neumeister A., Pirker W., Asenbaum S., Vitouch O., et al. [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biological Psychiatry 47 (2000) 482-489
32. Willeit M., Sitte H.H., Thierry N., Michalek K., Praschak-Rieder N., Zill P., et al. Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology 33 (2008) 1503-1513
33. Williams J.B. A structured interview guide for the Hamilton depression rating scale. Archives of General Psychiatry 45 (1988) 742-747
34. Williams JBW, Link MJ, Rosenthal NE, Amira L, Terman M. Structured interview guide for the Hamilton depression rating scale - seasonal affective disorder version, 2002 rev. New York, NY: New York State Psychiatric Institute; 2002.
35. Winkler D., Pjrek E., Iwaki R., and Kasper S. Treatment of seasonal affective disorder. Expert Reviews of Neurotherapeutics 6 (2006) 1039-1048
36. Winkler D, Pjrek E, Konstantinidis A, Kasper S. Drug therapy of seasonal affective disorder. In: Partonen T, Pandi-Perumal SR, editors. Seasonal affective disorder. Oxford: Oxford University Press; [in press].